Evidence map›Paper›PMID 30515595›Full record

ReviewWorld journal of urology2019

Emerging therapies in the management of high-risk non-muscle invasive bladder cancer (HRNMIBC).

Ryan P Werntz, Brittany Adamic, Gary D Steinberg

Abstract readReview
PubMed Publisher
In one paragraph

Review in World journal of urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ryan P WerntzSection of Urology, Department of Surgery, The University of Chicago Medicine, Chicago, 5841 S. Maryland Avenue, MC 6038, Chicago, IL, 60637, USA. ryan.werntz@uchospitals.edu.
Brittany AdamicSection of Urology, Department of Surgery, The University of Chicago Medicine, Chicago, 5841 S. Maryland Avenue, MC 6038, Chicago, IL, 60637, USA.
Gary D SteinbergSection of Urology, Department of Surgery, The University of Chicago Medicine, Chicago, 5841 S. Maryland Avenue, MC 6038, Chicago, IL, 60637, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBCG is the gold standard in management of high-risk non-muscle invasive bladder cancer (HRNMIBC). However, in patients who fail BCG, there are few effective intrasvesical options. This review aims to explore standard and emerging therapies in HRNMIBC.

methodsA non-systematic literature review was performed using Medline and PubMed. Literature focused on HRNMIBC and BCG failure studies, with particular attention to Phase II and III clinical trials.

resultsThe only FDA approved therapy for BCG failure patients in Valrubicin. Patients with HRNMIBC and BCG failure patients are at increased risk for progression and death from bladder cancer. There are a variety of clinical trials exploring different therapeutic approaches such as immunotherapy, vaccines, radiotherapy, and gene therapy. These trials are showing some promise in the early reporting phase.

conclusionDespite limited intravesical treatment options in BCG failure patients, there are several promising therapies currently being developed and several with promising early results.

Indexed as

Adjuvants, ImmunologicAntineoplastic AgentsBCG VaccineHumansNeoplasm InvasivenessRisk AssessmentUrinary Bladder NeoplasmsAdjuvants, ImmunologicAntineoplastic AgentsBCG VaccineBCG failureImmunotherapyNon-muscle invasive bladder cancerVaccines

Identifiers

PMID30515595

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.